Researcher
Steven De Jonghe
- Disciplines:Microbiology, Systems biology, Laboratory medicine
Affiliations
- Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Member
From1 May 2017 → Today - Medicinal Chemistry (Rega Institute) (Division)
Member
From18 Feb 2002 → 30 Apr 2017
Projects
1 - 10 of 18
- Synthesis of agonists for the C-C chemokine receptor type 5 (CCR5), derived from a substituted 4-aminopiperidinyl lead structureFrom1 Jan 2023 → TodayFunding: BOF - doctoral mandates
- Optimisation of a triterpene lead compound for the development of pan-anticoronavirus drugs targeting nsp15From3 Jan 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Synthesis and structure-activity relationship studies of CCR8 agonists as a novel treatment option for autoimmune diseasesFrom27 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The synthesis of novel CXCR4 antagonists for use in oncology and molecular imagingFrom1 Oct 2020 → 30 Sep 2021Funding: BOF - postdoctoral mandates
- An NMR facility tailored for biomedical researchFrom1 May 2020 → TodayFunding: FWO Medium Size Research Infrastructure
- Synthesis of nucleoside analogues as antiviral and antibacterial agentsFrom10 Feb 2020 → 10 Feb 2024Funding: Own budget, for example: patrimony, inscription fees, gifts
- Development and application of NanoBRET-based technology: Unravelling signalling bias at the human chemokine receptors CXCR1 and CXCR2From3 Sep 2019 → 3 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Synthesis of CXCR2 and CCR7 chemokine receptor antagonists targeting a conserved intracellular binding siteFrom3 Oct 2018 → 10 Jan 2023Funding: BOF - doctoral mandates
- Establishment of in vitro assays for the discovery of GPCR small molecule ligandsFrom30 May 2018 → 30 May 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- IN SEARCH FOR SUGAR, BASE OR PHOSPHATE MODIFIED NUCLEOSIDES ACTIVE AGAINST RNA VIRUSESFrom30 Nov 2017 → 7 Mar 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
11 - 20 of 129
- Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects(2023)
Authors: Dirk Jochmans, Johan Neyts, Steven De Jonghe, Pieter Leyssen
- Synthesis and structure-activity relationship study of phenoxybenzylpiperazine analogues as CCR8 agonists(2023)
Authors: Yenthel Verhaegen, Stijn Anthonissen, Tom Van Loy, Dominique Schols, Wim Dehaen, Steven De Jonghe
- Comprehensive study of alkaloids from Scadoxus multiflorus by HPLC-PDA-SPE-NMR and evaluation of their anti-SARS-CoV-2 activity(2023)
Authors: Steven De Jonghe, Johan Neyts, Christophe Pannecouque
Pages: 156 - 162 - Synthesis and cancer cell cytotoxicity of 2-aryl-4-(4-aryl-2-oxobut-3-en-1-ylidene)-substituted benzothiazepanes(2023)
Authors: Steven De Jonghe, Dominique Schols
Pages: 117 - 123 - Synthesis and biological evaluation of new CXCR4 antagonists(2023)
Authors: Mastaneh Safarnejad Shad, Wim Dehaen, Steven De Jonghe
- Optimization of triazolo[4,5-d]pyrimidines towards human CC chemokine receptor 7 (CCR7) antagonists(2023)
Authors: Tom Van Loy, Dominique Schols, Wim Dehaen, Steven De Jonghe
- Anti-SARS-CoV-2 Activity and Cytotoxicity of Amaryllidaceae Alkaloids from Hymenocallis littoralis(2023)
Authors: Steven De Jonghe, Johan Neyts, Christophe Pannecouque
- Exploration of Pyrido[3,4-d]pyrimidines as Antagonists of the Human Chemokine Receptor CXCR2(2023)
Authors: Katrijn Boon, Tom Van Loy, Dominique Schols, Wim Dehaen, Steven De Jonghe
- Identification of Z-Tyr-Ala-CHN2, a Cathepsin L Inhibitor with Broad-Spectrum Cell-Specific Activity against Coronaviruses, including SARS-CoV-2(2023)
Authors: Steven De Jonghe, Pieter Leyssen, Johan Neyts, Ellen Van Damme
- The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir(2023)
Authors: Dirk Jochmans, Kim Donckers, Bert Vanmechelen, Piet Maes, Steven De Jonghe, Johan Neyts
Patents
1 - 10 of 10
- Isoquinoline and pyridine based cxcr4 antagonists (Inventor)
- Prodrugs of nucleoside phosphonates (Inventor)
- Novel prodrugs of nucleoside phosphonates (Inventor)
- Prodrugs of fluorinated acyclic nucleoside phosphonates (Inventor)
- Antiviral activity of bicyclic heterocycles (Inventor)
- Antiviral compounds, a process for their preparation, and their use for treating viral infections (Inventor)
- Prodrugs of fluorinated acyclic nucleoside phosphonates (Inventor)
- Purine analogues and their use as immunosuppressive agents (Inventor)
- Novel prodrugs of nucleoside phosphonates (Inventor)
- Gak modulators as antivirals (Inventor)